Breaking News
Get 45% Off 0
💰 With a 129% YTD gain in the bag, these are our AI’s top global picks for March
Read now

Top Research Reports For Merck, UPS & Caterpillar

By Zacks Investment ResearchStock MarketsNov 10, 2017 05:27AM ET
www.investing.com/analysis/top-research-reports-for-merck-ups--caterpillar-200264353
Top Research Reports For Merck, UPS & Caterpillar
By Zacks Investment Research   |  Nov 10, 2017 05:27AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
CAT
+2.72%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
FDX
+1.65%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MRK
+0.69%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
DISH
+0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AAPL
+1.59%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
APC
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Friday, November 10, 2017

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), UPS (UPS) and Caterpillar (NYSE:CAT) (CAT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Merck’s shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the last year, losing -12.1% versus +13.2%. Merck beat estimates for earnings while missing the same for sales in Q3. Merck’s new products like Keytruda and Zepatier should continue to contribute meaningfully to the top line.

Keytruda is gaining strong momentum from the new indication of first-line lung cancer. The Keytruda development program also significantly advanced this year with several key regulatory approvals. Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line.

However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competition in the immuno-oncology market is also a significant concern. The recent delay in the readout from an important lung cancer study and withdrawal of a European application for Keytruda+chemo in first-line lung cancer were disappointing.

(You can read the full research report on Merck here >>>).

Shares of UPS have underperformed the Zacks Air Freight and Cargo industry as well as rival FedEx (NYSE:FDX) on a year-to-date basis. While UPS has lost -1.9% of its value, the industry it belongs to and FedEx have rallied +4.6% and 16.8%, respectively, in the same period. In the third quarter of 2017, the company reported better-than-expected earnings per share and revenues despite the effect of recent hurricanes.

Moreover, both metrics improved on a year-over-year basis. The upside was driven by growth across all the key segments of the company. UPS also expects the upcoming holiday season to be a highly successful one on the back of the growing demand for e-commerce.

However, high costs are limiting bottom-line growth as the company is making significant investments to upgrade its facilities. Furthermore, foreign currency-related headwinds seem to hurting results, as UPS operates globally.

(You can read the full research report on UPS here >>>).

Strong Buy-rated Caterpillar’s have gained +46% year-to-date, outperforming the Zacks Construction and Mining industry which has increased +44.3% over the same period. Caterpillar delivered another upbeat quarter with adjusted earnings per share surging 129% year over year and revenues rising 25%.

Both beat respective expectations aided by strong demand for construction equipment in North America, robust sales in China and cost-control efforts. Caterpillar hiked 2017 guidance, to revenues of $44 billion and earnings per share of $6.25. The mid-point of the ranges reflects a year-over-year growth of 14% and 83%, respectively. Higher sales in Asia Pacific and North America, improved order rates and backlog will fuel growth in Construction Industries.

Resource Industries will gain on higher aftermarket parts sales. Energy & Transportation will be buoyed by improved sale of engines into industrial applications, strength in onshore North America oil and gas and transportation. Further, ongoing efforts to reduce costs will help boost margins.

(You can read the full research report on Caterpillar here >>>).

Other noteworthy reports we are featuring today Blackstone (NYSE:BX) (BX), Delta (DAL) and Anadarko (APC).

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

Mark Vickery

Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read
Featured Reports

Strategic Initiatives Aid Huntington (HBAN), High Costs a Woe

Per the Zacks analyst, Huntington's strategic initiatives, including expansionary moves and rise in loans should bolster revenue growth. However, escalating costs is an unfavorable factor.

Anadarko's (APC) Oil Focus Benefits, Dry Hole Expenses Ail

The Zacks analyst believes Anadarko Petroleum (NYSE:APC)'s focus to produce more oil will benefit the company, but the rising dry hole expenses are a concern

PRASM Growth Buoys Delta (DAL), High Costs Ail

The Zacks analyst likes Delta's performance with respect to passenger unit revenues (PRASM). Capacity discipline related efforts also encourage.

MGM Resorts' (MGM) Vegas Business Solid, Macau a Concern

Despite the Las Vegas shooting, improving economy and tourism in the region may drive growth at MGM Resorts, per the Zacks analyst. In spite of Macau revival, weak results at MGM China raise concerns.

Fund Accessibility Aids Blackstone (BX), Dividend May Falter

The Zacks analyst thinks Blackstone's fund raising capability remains strong, reflecting continued revenue growth.

Loan Growth Support M&T Bank's (NYSE:MTB) Revenue, High Costs a Woe

Per the Zacks analyst, organic growth remained a key strength at M&T Bank, as reflected by rising loans and deposits aiding revenue growth.

International Paper (IP) Margins Marred by Pension Woes

Per the Zacks analyst, International Paper is taking prudent steps to drive margin expansion although high pension obligations remain a major headwind.

New Upgrades

Order Growth, Dividend Payouts Aid Huntington Ingalls (HII)

Per the Zacks analyst, solid order inflows for Huntington Ingalls' ships and submarines are boosting its revenue growth. Moreover, the company pays lucrative dividends that attract more investors.

Marathon (MPC) Buoyed by Refining Margins, Speedway Assets

Apart from strong refining margin environment, the Zacks analyst believes that the Speedway convenience store business will help Marathon Petroleum (NYSE:MPC) to generate healthy merchandise profits.

Amdocs (DOX) Poised to Benefit from Continuous Project Wins

Per the Zacks analyst, Amdocs is poised to record healthy revenue growth in fiscal 2018 with diligent execution of operational plans, strategic acquisitions and continuous project wins.

New Downgrades

Weakness in Generic Segment Weighs on Mallinckrodt (NYSE:MNK)

Per the Zacks analyst, weakness in generic segment and lower Acthar sales due to challenging payer environment will adversely impact Mallinckrodt's growth trajectory.

Jazz Pharma's (JAZZ) Xyrem Shows Lower Growth in 2017

Jazz's key drug Xyrem is being negatively impacted by unfavorable payer mix and delayed prescription fulfillment. This might further hurt the top-line in the near term, believes the Zacks analyst.

Dwindling Customer Base, OTT Threat Weighs on DISH (DISH)

DISH Network (NASDAQ:DISH) has lost massive pay-TV and broadband subscribers due to stiff competition in the segment. The Zacks analyst does not find any near-term catalyst for the company.



United Parcel Service, Inc. (NYSE:UPS): Free Stock Analysis Report

Merck & Company, Inc. (NYSE:MRK): Free Stock Analysis Report

Delta Air Lines, Inc. (NYSE:DAL): Free Stock Analysis Report

Caterpillar, Inc. (CAT): Free Stock Analysis Report

The Blackstone Group L.P. (BX): Free Stock Analysis Report

Anadarko Petroleum Corporation (APC): Free Stock Analysis Report

Original post

Zacks Investment Research

Top Research Reports For Merck, UPS & Caterpillar
 

Related Articles

Adam Hamilton
Big US Stocks’ Q4’24 Fundamentals By Adam Hamilton - Mar 07, 2025

The big US stocks dominating markets and investors’ portfolios just finished another earnings season. They reported spectacular collective results including record sales, profits,...

Top Research Reports For Merck, UPS & Caterpillar

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email